Diego Díaz García, Medical Oncologist, CEO and Founder of CánCare, posted on X:
“Are we overestimating success in ph3 oncology trials?
Only 6% of ph3 oncology RCTs show improvement in both OS and QoL.
Most “positive” trials rely on surrogate endpoints, often without adjusting QoL for baseline. We must refocus trials on what truly matters to patients.”
Title: Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials
Authors: Alexander D. Sherry, Avital M. Miller, Jnana Preeti Parlapalli, Gabrielle S. Kupferman, Esther J. Beck, Jordan McDonald, Ramez Kouzy, Joseph Abi Jaoude, Timothy A. Lin, Nina N. Sanford, Fumiko Chino, Bishal Gyawali, Christopher Booth, Pavlos Msaouel, Ethan B. Ludmir
Read The Full Article at JAMA Oncology.
More posts featuring Diego Díaz García.